The direct answer for any supplement brand owner weighing whether to outsource to an OEM or build in-house manufacturing in 2026: for brands doing under USD 8-12 million in annual COGS, OEM beats in-house on every metric (capex, opex, lead time, regulatory exposure, opportunity cost). For brands above USD 15-20 million in annual COGS with stable, single-formula products, in-house starts to make TCO sense, but only with a 5-7 year horizon, deep operational depth on the leadership team, and disciplined demand planning. For brands between USD 10-15 million, it’s a coin flip that depends on product complexity, regulatory geography, and growth trajectory. Below is the full TCO model with real numbers, so the decision isn’t a guess.

Why this comparison is almost always answered incorrectly

When a brand owner asks “should we build in-house?” the typical decision is made on gross margin alone: “We pay our OEM USD 4/bottle; if we built in-house at USD 1.50/bottle, we’d save USD 2.50/bottle × 100,000 bottles/year = USD 250k/year.” The conclusion is “build.”

This reasoning misses 80% of the cost structure. A true TCO model has to include capex amortisation, regulatory exposure, opportunity cost of capital, and the operational complexity of running a GMP facility. Once those are added, the breakeven volume is typically 3-5× higher than the gross-margin math suggests.

The full 3-year TCO model

Comparing two scenarios for a hypothetical supplement brand doing 100,000 bottles/year:

Scenario A: OEM partnership (Bionutricia or equivalent)
– Per-unit cost: USD 4.20 at 100,000 unit annual volume
– Annual COGS: USD 420,000
– Brand-side overhead: ~USD 40,000/year (procurement officer + QA reviewer at fractional FTE)
– Working capital tied up in inventory: ~USD 90,000 (90 days inventory)
– Regulatory exposure: low (OEM holds JAKIM, FSSC, US FDA, GMP)
– Capex: USD 0
– 3-year total cost: USD 1,470,000 (COGS 1.26M + brand overhead 120k + inventory carrying cost ~90k)

Scenario B: In-house manufacturing (new build)
– Capex: facility build-out (USD 800,000-1,500,000 for a basic supplement plant), equipment (USD 400,000-900,000 for sachet-filling line + tablet press + blending tanks + bottle filler + QC lab), licences and certs setup (USD 80,000-150,000)
– Annual opex: facility lease and utilities (USD 120,000-220,000), staff (10-18 FTE at USD 35,000 average loaded cost = USD 350,000-630,000), raw materials (USD 200,000-280,000 for the same 100k bottles annual volume), maintenance + consumables (USD 40,000-70,000), recurring cert audits (USD 25,000-45,000)
– Annual COGS at scale: USD 1.50-2.20 per bottle (if everything runs perfectly)
– Working capital tied up in inventory + raw materials: USD 250,000-400,000
– Regulatory exposure: high — the brand bears full liability for any audit finding, recall, contamination event
– Opportunity cost of capital: USD 1.2M-2.5M tied up in facility/equipment that could otherwise be deployed in marketing, R&D, or other growth
– 3-year total cost: USD 3,800,000-5,500,000 (capex 1.3-2.5M + opex 2.2-3.0M − net of any savings)

At 100,000 bottles/year, OEM is ~2.5-4× cheaper on TCO. The “savings” from in-house manufacturing don’t appear in the model until annual volume exceeds approximately 350,000-500,000 bottles — at which point the fixed overhead of an in-house facility is finally amortised enough to compete with OEM per-unit pricing.

The volume threshold that flips the math

Approximate breakeven volume for in-house to win on TCO:

A brand doing under 250,000 bottles/year is almost always better off staying with an OEM. A brand doing over 1 million bottles/year of a single stable formula should seriously consider in-house — but even then, OEM may make sense for new product launches and second/third SKUs that haven’t proven volume yet.

Five hidden costs of in-house that don’t show in basic gross-margin math

Hidden cost 1: Regulatory liability exposure. When the brand owns the factory, the brand is named in any FDA Form 483 observation, JAKIM revocation, or class-action arising from a contamination event. Insurance helps but doesn’t eliminate the risk; reputable insurers won’t underwrite supplement manufacturers without GMP audit history, which itself takes 2+ years to establish.

Hidden cost 2: Inventory + raw material working capital. OEMs ship Just-In-Time; in-house manufacturing requires holding 90-180 days of raw materials AND 30-90 days of finished goods. For a 100k-bottle-per-year brand, that’s an extra USD 150k-300k of working capital perpetually tied up.

Hidden cost 3: Operational distraction. A supplement factory is a complex operation requiring dedicated leadership attention — production planning, quality management, regulatory compliance, vendor management, staff hiring/training. For founder-led or marketing-led brands, this attention is taken from product development, brand-building, and sales — where the higher ROI usually lives.

Hidden cost 4: Single-point-of-failure risk. OEMs run on parallel lines and have backup capacity. In-house manufacturing concentrates the brand’s entire supply on a single facility. A fire, a labour dispute, an equipment failure, or a regulatory action shuts the brand down. Brands that build in-house typically maintain a secondary OEM relationship as insurance — which adds back cost.

Hidden cost 5: Capability constraint on product innovation. OEMs invest in new technology (liposomal encapsulation, nano-emulsification, novel delivery formats) because it’s their core competency. A single-brand in-house facility can’t justify the same R&D investment, which means the brand gradually falls behind on product innovation. This is the slowest but most damaging hidden cost.

When in-house DOES make sense

Three conditions where in-house manufacturing is the right answer:

Condition 1: The brand has a single, high-volume, stable formula (e.g., a Vitamin D3 supplement that has sold 2M+ bottles/year for 3+ years without formula changes). The volume justifies the capex, and the stability removes the formulation-development complexity that OEMs handle well.

Condition 2: The brand has proprietary IP that requires factory-level secrecy. Some innovations are hard to protect via NDA alone — patented manufacturing processes, novel encapsulation methods, proprietary formulations. Bringing manufacturing in-house removes the disclosure to a third party.

Condition 3: The brand operates in a regulatory geography where in-house is required. Some jurisdictions (Saudi Arabia for certain pharmaceutical-adjacent products, Vietnam for some categories) effectively require local in-country manufacturing for full market access. A geographic moat may justify the in-house build.

Outside of these three conditions, OEM is almost always the right answer even at higher revenue scales — because the OEM specialist beats the in-house generalist on operational quality.

The hybrid model — the right answer for most brands above USD 5M

Most successful supplement brands at the USD 5-30M revenue range use a hybrid model:

• Core SKUs at high stable volume → OEM with long-term contract pricing
• New SKU launches → OEM with pilot MOQ + scale-up tiers
• Premium / proprietary SKUs → OEM with NDA + IP-protective contract terms (or selective in-house for the most sensitive)
• Geographic-specific SKUs → local OEM in the destination region

This model captures most of the cost advantage of in-house (at the high-volume end) while preserving the speed and capability advantage of OEM (at the innovation end). It’s also significantly less capital-intensive than full in-house.

Bionutricia’s typical brand partner profile fits exactly this hybrid pattern — a brand at the USD 2-15M revenue range running 80-100% of production through OEM, with the option to scale select SKUs into long-term contract pricing as volume stabilises.

How to model your own TCO

For a brand owner evaluating the OEM vs in-house decision specifically:

1. Project annual unit volume for the next 5 years (use realistic growth assumptions, not best-case).
2. Compare per-unit OEM cost at projected volume tiers vs blended in-house per-unit cost (factoring capex amortisation across years 1-5).
3. Add the 5 hidden costs explicitly to the in-house side.
4. Add the opportunity cost of the capex (what could the USD 1.5-2.5M earn deployed in marketing or R&D instead?).
5. Stress-test with a regulatory event simulation: what if there’s an FDA Form 483 in year 2? What if JAKIM revokes certification temporarily?

If after that full model the in-house TCO is still 30%+ cheaper than OEM TCO over a 5-year horizon, in-house may be justified. If the model is within 30%, OEM almost always wins on risk-adjusted basis.

Bionutricia’s positioning in this debate

Bionutricia (Est. 2006) brings the operational maturity that takes a new in-house facility 3-5 years to build. 239+ brand partners means we’ve seen most of the volume curves and growth trajectories that a brand might fit. JAKIM + FSSC 22000 + US FDA + Kosher + Patent stack means the regulatory exposure stays on our side, not yours. Multi-line capacity (powder/liquid/gel sachet, chewable tablet, liquid bottle, pouch beverage) means a brand can run multi-SKU production in parallel without owning the equipment. MOQ from 1,000 units means a new formula gets tested at small scale before any commitment.

For the right brand profile, this is structurally cheaper, faster, and lower-risk than in-house — and the brand owner retains capital for the activities (marketing, R&D, distribution) that actually grow revenue.

📚 Related guides

• How much does it cost to manufacture a private-label supplement in Malaysia?
• Top 7 nutraceutical OEM manufacturers in Malaysia compared (2026)
• OEM manufacturing for direct-selling brands

Frequently asked questions

At what volume does in-house supplement manufacturing become cheaper than OEM?
On a basic gross-margin basis, in-house starts to look cheaper around 250,000 bottles/year of a single formula. On a true TCO basis including hidden costs (regulatory, working capital, opportunity cost, single-point-of-failure risk), the breakeven is typically 500,000-1,000,000 bottles/year.

How much does it cost to build a supplement manufacturing facility?
USD 800,000-1,500,000 for the facility build-out, USD 400,000-900,000 for equipment, USD 80,000-150,000 for licences and initial certifications. Plus 12-24 months of operating cost before first revenue at scale.

Is OEM riskier than in-house?
In well-constructed OEM contracts, no — the OEM bears regulatory liability for manufacturing, the OEM has multi-line backup capacity, and the brand can move to a secondary OEM if needed. In-house concentrates risk on a single facility owned by the brand.

Can a brand do hybrid — some OEM and some in-house?
Yes, and this is the most common model for established brands at the USD 5-30M revenue range. Core stable SKUs run in-house; new launches and innovative formulations run through OEMs.

How long does it take to set up an in-house supplement factory?
24-36 months from decision to production-ready, including facility build-out, equipment procurement, staff hiring, GMP certification, and JAKIM/FSSC certification. OEM partnership goes from contract to first shipment in 14 weeks.

Ready to model your supplement brand’s true OEM vs in-house cost with real numbers?

20+ years OEM experience. 239+ brand partners across SEA, MENA, US, EU. Tiered pricing from 1,000 units. Full cert stack (JAKIM, FSSC 22000, US FDA, Kosher). Patented liposomal IP. 24-hour RFQ reply.

Request a quotation · See our OEM services · View our facilities

WhatsApp: +60 16-661 8510

Article by Bionutricia R&D Team. Last updated: June 10, 2026.